We are live on
!
Find out more
FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$237M
1-Year Est. Return
107.53%
This Fund
S&P 500
This Quarter
Est. Return
+68.73%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$205M
AUM Growth
+$124M
(+153%)
Cap. Flow
+$66.7M
Cap. Flow
% of AUM
32.48%
Top 10 Holdings %
Top 10 Hldgs %
99.39%
Holding
18
New
7
Increased
2
Reduced
2
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Keros Therapeutics
KROS
|
+$44M |
| 2 |
Vaxcyte
PCVX
|
+$20M |
| 3 |
GBIO
Generation Bio
GBIO
|
+$19.1M |
| 4 |
Kura Oncology
KURA
|
+$17.5M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
+$8.21M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$15.1M |
| 2 |
Insmed
INSM
|
+$10.9M |
| 3 |
Cytokinetics
CYTK
|
+$10.7M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$5.32M |
| 5 |
AERI
Aerie Pharmaceuticals
AERI
|
+$3.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Keros Therapeutics
KROS
$199M
| $53.6M | 26.09% |
+1,428,071
| New | +$44M |
|
|
2
Cytokinetics
CYTK
$10.5B
| $37.9M | 18.45% |
1,607,292
-570,000
| -26% | -$10.7M |
|
|
3
Kura Oncology
KURA
$800M
| $21.3M | 10.39% |
1,307,982
+1,214,982
| +1,306% | +$17.5M |
|
4
Fulcrum Therapeutics
FULC
$273M
| $20.7M | 10.1% |
1,133,948
+135,293
| +14% | +$2.13M |
|
|
5
Vaxcyte
PCVX
$7.81B
| $19.6M | 9.56% |
+620,821
| New | +$20M |
|
|
GBIO
6
DELISTED
Generation Bio
GBIO
| $18M | 8.78% |
+85,794
| New | +$19.1M |
|
|
MYOK
7
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $12.2M | 5.95% |
126,492
-180,908
| -59% | -$15.1M |
|
|
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
| $9.93M | 4.83% |
+2,843,893
| New | +$8.21M |
|
9
Voyager Therapeutics
VYGR
$183M
| $6.52M | 3.18% |
516,751
| – | – |
|
10
Oric Pharmaceuticals
ORIC
$1.15B
| $4.22M | 2.05% |
+125,000
| New | +$3.99M |
|
|
DRNA
11
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $635K | 0.31% |
+25,000
| New | +$539K |
|
12
Travere Therapeutics
TVTX
$5.2B
| $612K | 0.3% |
+30,000
| New | +$478K |
|
|
BLUE
13
DELISTED
bluebird bio
BLUE
| – | – |
-3,860
| Closed | -$2.3M |
|
|
14
Insmed
INSM
$21.4B
| – | – |
-678,322
| Closed | -$10.9M |
|
15
Kiniksa Pharmaceuticals
KNSA
$5.8B
| – | – |
-65,000
| Closed | -$1.01M |
|
16
uniQure
QURE
$3.03B
| – | – |
-19,082
| Closed | -$905K |
|
|
AERI
17
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-227,717
| Closed | -$3.07M |
|
|
BHVN
18
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – |
-156,355
| Closed | -$5.32M |
|
Similar funds
BCM
AG
FL
PVM
MFA
TCM
WW
CB
Foresite Capital Management IV's Q2 2020 Portfolio in Review
As of Q2 2020, Foresite Capital Management IV held 18 positions worth $205M, up 153% from $81.1M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Foresite Capital Management IV deployed $66.7M of net new capital in Q2 2020, opening 7 new positions and adding to 2 existing holdings. Its largest new stake was Keros Therapeutics: 1,428,071 shares worth $53.6M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.
On the sell side, the largest reduction was MyoKardia, Inc. Common Stock, an estimated $15.1M trimmed.
- Foresite Capital Management IV's largest Q2 2020 buy was Keros Therapeutics: 1,428,071 shares worth $53.6M.
- Foresite Capital Management IV added most to Kura Oncology in Q2 2020, an estimated $17.5M increase.
- Foresite Capital Management IV's biggest Q2 2020 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $15.1M.
- Foresite Capital Management IV fully exited Insmed in Q2 2020, selling an estimated $10.9M.
- Foresite Capital Management IV's ten largest holdings make up 99% of its $205M portfolio in Q2 2020.
- Foresite Capital Management IV opened 7 new positions and closed 6 in Q2 2020.
- Foresite Capital Management IV's portfolio value rose 153% quarter-over-quarter to $205M.
Based on Foresite Capital Management IV's 13F filing for Q2 2020, filed 13 Aug 2020.